Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN)
$0.88
-0.0100 ( -1.12% ) 50.0K
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Market Data
Open
$0.88
Previous close
$0.89
Volume
50.0K
Market cap
$4.51M
Day range
$0.86 - $0.90
52 week range
$0.83 - $10.09
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Mar 06, 2024 |
10-q | Quarterly Reports | 54 | Feb 14, 2024 |
8-k | 8K-related | 15 | Feb 14, 2024 |
8-k | 8K-related | 14 | Feb 01, 2024 |
8-k | 8K-related | 14 | Jan 29, 2024 |
8-k | 8K-related | 12 | Dec 27, 2023 |
8-k | 8K-related | 12 | Dec 15, 2023 |
10-k | Annual reports | 78 | Dec 14, 2023 |
8-k | 8K-related | 13 | Dec 14, 2023 |
4 | Insider transactions | 1 | Oct 27, 2023 |